通过对抑郁症进行系统查,改善帕金森病的治疗
Connie Marras1, Zachary Meyer2, Hongliang Liu3
1The Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Movement disorders clinical practice
|July 20, 2024
概括
对帕金森病 (PD) 患者实施正式抑郁查显著增加了检测率. 量身定制的临床过程对于克服实施障碍和改善患者护理至关重要.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 改善临床实践的改善
背景情况:
- 抑郁症是帕金森病 (PD) 中普遍但未被认可的并发症.
- 建议在PD护理中对抑郁症进行系统查,但尚未得到广泛采用.
- 当前的临床实践往往缺乏PD患者的正式抑郁症评估工具.
研究的目的:
- 评估在帕金森病患者的运动障碍诊所实施正式抑郁查工具的可行性和影响.
- 评估正式抑郁症查率的增加,并确定实施障碍.
- 检查查对PD患者抑郁症评分的影响.
主要方法:
- 15项老年抑郁量表 (GDS-15) 在5个运动障碍诊所实施.
- 开发了特定站点的工作流程,并与临床医生和患者进行了定性访谈.
- 在实施之前和之后分析了查率,不进行查的原因和抑郁症得分.
主要成果:
- 正式查增加了近五倍,88%的PD患者在研究期间进行了查.
- 老年抑郁量表 (GDS-15) 在59%的查中被使用,比基线大幅上升.
- 完成GDS-15的45%患者的抑郁查结果呈阳性,随后的随访显示抑郁症得分有显著改善.
结论:
- 使用像GDS-15这样的仪器进行正式的抑郁查,在帕金森病护理中可以达到更高的比率.
- 临床医生的时间和后勤挑战等障碍存在,但可以通过特定网站的流程来管理.
- 优化查率需要针对个别临床环境量身定制的实施策略.
更多相关视频
10:28Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
15.2K
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
相关概念视频
Parkinson's Disease: Treatment
244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
Parkinson's Disease: Overview
517
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
517
